INTRODUCTION
One out of six men will be diagnosed with prostate cancer during their lifetime (1). However, using current risk stratification strategies it is still difficult to separate patients with rapidly progressing tumors, which require aggressive treatment, from those with indolent tumors.
The result is over treatment, leading to undesirable side affects for a large population of men and unnecessary consequential healthcare costs (2) . Therefore, it is essential that new biomarkers are uncovered that better predict outcome of the disease and hence enable better individual treatment decisions.
Cancer biomarkers provide a potentially powerful tool in the diagnosis / prognosis of cancer patients. In prostate cancer, the commonly used biomarker is PSA, a protein antigen specific to prostate tissue, which is measured in the blood and elevated in prostate cancer.
Unfortunately, PSA alone is a poor predictor of disease outcome (3) . Recently, microRNAs (miRNAs) have been found in serum and have been proposed as potential biomarkers of normal physiology and disease (4) . MiRNAs are short (18-24 nucleotides), non-coding RNAs, which regulate gene expression post-transcriptionally by both destabilizing messenger RNAs (mRNA) and inhibiting their translation. Canonical miRNAs derive from longer polymerase II transcripts, called pri-miRNAs. A complex consisting of the proteins DGCR8 and Drosha process the pri-miRNAs to pre-miRNAs, which are then exported to the cytoplasm and cleaved by the protein Dicer to mature miRNAs. Exceptions to this processing include non-canonical miRNAs that bypass DGCR8/Drosha, while still being processed by Dicer. Knockout models of Dgcr8 and Dicer have been developed that remove only canonical miRNAs or both canonical and non-canonical miRNAs respectively (5-7).
For prostate cancer tissue there have been very few studies that compared miRNA expression levels in more than 10 benign and malignant samples (8) (9) (10) (11) . Noticeably, there is In total 6 prostate cancer patient samples were studied, from which 5 were from patients in advanced prostate cancer stages (3 and 4) and only one sample was from a non-advanced stage. Four of the total 6 prostate cancer patients in this study had received systemic chemotherapy (Taxotere or Lupron with/without the bisphosphonate Zometa). Therefore it remains unclear whether the altered serum miRNA levels are a result of the chemotherapy or reflect the actual advanced cancerous disease (15) .
To establish a method for identifying miRNA signatures that could provide diagnostic and prognostic information for prostate cancer patients prior to any treatment, we developed a novel multiplex qRT-PCR method and tested 4 sets of patients (12 patients in each set) with differing risk stratifying CAPRA scores. Due to the inconsistency of previous profiling experiments (12) 
Statistical Analysis
The initial data for statistical analysis were the ∆Ct values for each sample. Seventy out of 384 microRNAs were positive in at least one set of patients and, therefore, went into the final analysis. There were 38 samples analyzed, since some samples had to be excluded due to technical problems and red blood cell lysis. Of these, 9 were healthy controls, 9 had a low-, 11 had an intermediate-and 9 had a high CAPRA score. The remaining data was normalized for every sample and multiplex by subtracting the corresponding median.
Complete linkage hierarchical clustering with correlation as the distance metric was performed using Gene Cluster 3.0. To compare expression levels between groups, the t-test was used. To examine trends in expression across more than two groups, linear regression was utilized. Then 12 top candidates from these analyses were validated using single-plex qRT-PCR. To adjust for multiple comparisons, p-values were converted to q-values using the method of Benjamini and Hochberg (21). The cutoff for statistical significance was a qvalue less than 0.05. Reciever operating curves were generated using the binormal method and the web based calculator for ROC curves. AUCs were automatically calculated and provided with individual ROCs (22). 
RESULTS

Optimization of multiplex qRT-PCR
To identify miRNA signatures that diagnose and correlate with prostate cancer prognosis, we set out to establish a robust profiling method that could be used on patient sera. As the levels of small RNAs in serum are likely to be very low, a multiplex RT-PCR based quantification method was evaluated. RSL-P, FP and TaqMan probes were generated for all annotated human miRNAs (20) (miRBase Version 11 Dicer knockout (lacking canonical and noncanonical miRNAs) cells, serving as optimal negative controls. Surprisingly, while many miRNAs showed lower levels in knockout cells as expected, several expressed miRNAs were not detected at all and some showed even increased levels in the knockouts relative to wild-type ESC (Fig.2a) . This finding suggested a lack of accuracy in the previously published multiplex qRT-PCR technique.
We hypothesized that this lack of accuracy could be due to carry-over of the many primer sets from the multiplex pre-PCR step to the uniplex qPCR reactions. To test this hypothesis, pre-PCR products were purified away from primers following pre-PCR by size selection on native polyacrylamide gels ( Fig.1 and Supplementary Fig.2 online) . As expected, bands for the expected product sizes were seen in the wild-type, but not in the Dgcr8 or Dicer knockout ESC, while excessive primers were seen in all backgrounds ( Supplementary Fig.2 online).
The purified product was then subjected to uniplex qPCR reactions. showed little change or even increases in the Dgcr8 knockout cells (Fig.2b) . Evaluation of Dicer knockout ESCs showed a similar significant decrease of all canonical miRNAs as seen in the Dgcr8 knockout ESCs (Fig.2c) . Unlike the Dgcr8-, the Dicer knockout ESCs showed greater than 100-fold decrease in the non-canonical miRNAs (Fig.2c) . The detection of more miRNAs, the loss of false positive signals and the ability for correct classification of Dgcr8-independent, Dicer-dependent miRNAs show that adding a purification step in between pre-PCR and qPCR vastly improves robustness of the multiplex qRT-PCR protocol.
Alternative purification methods
To make the purification approach applicable for large sample sets we tested alternative methods of removing carryover of primers. ExoSAP-IT® successfully removed primers, but also led to partial degradation of the PCR product ( Supplementary Fig.3a online, lane 2). We hypothesized that degradation occurred during heat inactivation of the exonuclease as the short PCR products would likely begin to partially denature as temperature rose. Therefore, we avoided heat inactivation and directly purified the PCR products from the enzymatic reaction using spin columns (Quiagen MinElute®). Under these conditions, primers were into analysis since some samples had to be excluded due to technical problems and red blood cell lysis. 70 out of 384 miRNAs were present in all sera and therefore comparable between samples. Normalized absolute expression levels of all the expressed miRNAs were used for complete hierarchical clustering using Cluster 3.0. The unsupervised analysis segregated 8 out of 9 healthy patients into one cluster of size 9. There was also a trend toward clustering by CAPRA group (Fig.3a) . These findings suggest that miRNA signatures can both diagnose prostate cancer as well as segregate risk for progression.
Trends for individual miRNAs
To identify individual miRNAs from the screen that showed the most significant changes between healthy vs. all malignant and healthy vs. high-risk cancer sera, a pairwise comparisons using the t-test were performed.. This analysis identified twelve statistically significant candidates (miR-19a, -20b, -24, -26b, -30c, -93, -106a, -223, -451, -874, -1207-5p
and miR-1274a) (expression levels relative to healthy samples shown in Fig.3b ). Ten microRNAs (miR-20b, -24, -26b, -30c, -93, -106a, -223, -874, -1207-5p and miR-1274a) were All twelve top candidates from the screening were then validated by individual qRT-PCRs and statistically analyzed as the screening results. For miR-19a there was weak correlation between screen and follow-up PCR results. For miR-20b, the expression levels were higher in the cancer group vs the healthy group in the follow-up PCR, but the result was not stastically significant ( Supplementary Fig.4 online and Table 2 ). In ten cases (miR-24, -26b, -30c, -93, -106a, -223, -451, -874, -1207-5p and miR-1274a) Fluidigm® and individual PCR data produced statistically significant changes in the same direction ( Supplementary Fig.4 online). Specifically, miR-223, -26b, -30c and miR-24 were downregulated in the cancer group and miR-874, -1274a, -1207-5p, -93 and miR-106a were upregulated.
Among the 10 miRNAs, there were 7 distinct patterns (Figs.3b and 4) . Three miRNAs (miR-223, -874, and miR-1207-5p) showed significantly altered expression after the transition from healthy to cancer, but stable expression within the different risk stratified cancer sera. In particular, miR-223 showed a stable decrease, while miR-1207-5p and -874 showed a stable increase in the cancer patients relative to healthy controls (Figs.4a,b) . Two miRNAs showed a linear relationship between miRNA levels and cancer risk: miR-24 steadily decreased with risk, while miR-106a steadily increased with risk (Figs.4c,d ). Two miRNAs (miR-26b, -30c)
were down in the low and intermediate-risk groups relative to both healthy controls and 
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and again to metastatic disease was observed for miR-93 and -1274a (Fig.4f) . The final trend was an increase for miR-451 in the patients with the metastatic disease with little to no change in low-and intermediate-risk groups (Fig.4g) . P-values were determined and the data was adjusted for multiple comparisons (q-values) ( Table 2 ).
The 10 miRNAs were also evaluated for potential correlations with individual parameters of the CAPRA score among the cancer patient samples including PSA, Gleason, and Age
( Supplementary Figs. 5a-c online) . While some of the miRNAs showed trends with these parameters, none reached a level of significance.
Diagnostic utility of miRNA serum profiling
To further explore the diagnostic ability of the signature receiver operation characteristics Fig.6 online).
Prognostic utility of miRNA serum profiling
The uncovered miRNAs showed distinct differential expression levels for the different risk stratified groups (Fig.4) . Furthermore the analysis of unsupervised clustering of the individual serum samples also trended to, but not unambiguously differentiated, the individual risk of progression groups (Fig.3, Supplementary Fig.7 online) . The strong trends of serum miRNAs to correlate with the different risk groups indicate a promising prognostic potential, however there remained pronounced variability within the different groups (Fig.5) . Any marker that could provide additional prognostic information beyond that of the CAPRA score should show 
DISCUSSION
Here we describe an optimized multiplex qRT-PCR approach, which used in combination with a microfluidics platform, enabled us to screen 48 prostate cancer patient sera for alterations in miRNA levels. While previous smaller scale studies suggested the utility of plasma miRNAs in prostate cancer (14, 15) , this is the first study to evaluate miRNA levels in an untreated patient set with different risks of progression based on the leading risk indicator currently available. Identifying prostate cancer patients at risk for progression prior to treatment is an essential goal as current measures lead to a over-treatment of some patients and under-treatment of others (2, 3).
MiRNA signatures uncovered in this study not only distinguished sera from healthy and highrisk, but also healthy and curable disease stages (low and medium-risk) sera. Cluster and ROC analyses underscored the diagnostic potential of our serum miRNA signatures.
Importantly, the expression levels of the miRNA signatures also trended with CAPRA scores and were able to cluster samples in accordance to their CAPRA score, demonstrating the ability to further separate cancer patients according to their risk of recurrent cancer.
Interestingly the in-group variation indicated that serum miRNAs may have the potential to separate patients within the risk categories and may therefore provide additional information.
Investigating the potential of serum miRNAs to predict the clinical outcome and cancer behavior of prostate cancer patients in large-scale clinical trials will be required to confirm such a proposition.
Our modified qRT-PCR demonstrates that primer carryover from the multiplex PCR has detrimental effects on miRNA quantification. Purification of the PCR product and therefore removing multiplex primers prior to quantitative PCR led to 1) the detection of more microRNAs (increased sensitivity), 2) loss of false positive signals in Dgcr8 -/-and Dicer Noticeably in accordance to our findings, miR-106a and miR-30c appear to be over expressed in prostate cancer tissue samples compared to healthy prostate tissue (8) .
Furthermore, miR-93 is upregulated in prostate cancer tissue along with its host gene MCM7
(29, 30). Based on these associations, it will be important to determine the cell source and function of the miRNAs we find elevated and depressed in the sera of prostate cancer patients of different risk for progression. Table 2 : Significantly altered individual microRNAs.
The p-values shown above were determined using the t-test for comparison between groups and using linear regression to examine trends. Data was adjusted for multiple comparisons (q-values). * Note that miR-20b is not statistically significant. Data was median normalized and unsupervised complete hierarchical clustering with correlation as the distance metric was performed using Cluster 3.0 followed by Treeview.
a) Absolute expression levels of miRNAs that were expressed in all samples and therefore were used for sample comparison. The X-axis shows different risk groups individuals and the Y-axis shows miRNAs. 8 out of 9 healthy samples cluster together in one cluster of size 9.
There is also a trend toward clustering by Capra group.
b) Expression levels of the 12 most significantly altered miRNAs relative to healthy samples.
All candidates were then validated by individual qRT-PCRs on the standard platform (ABI HT-7900) and statistically analyzed as the screening results. (Table 2 ).
Figure 5: Inter and intra-group variability
The miRNAs trend to correlate with the different risk groups, however remaining in-group variability could provide additional information to current scoring indexes. Figure-1 Step 1: multiplex reverse transcription of 96 target microRNAs using 96 di erent and speci c reverse stem loop primers.
cDNA library for 96 microRNAs.
Step 2: multiplex pre-PCR using 96 di erent and speci c forward primers and universal reverse primers.
12-18 cycles preampli cation of 96-plex cDNA library.
Reaction tube content Schematic of Reaction B. With Puri cation
Preampli cation product after purifying away excessive primer-sets.
A. Without Puri cation
Preampli cation product including carry-over of primer sets and primer-dimers.
Step 
